Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours.
Br J Cancer
; 128(5): 886-895, 2023 03.
Article
em En
| MEDLINE
| ID: mdl-36526673
ABSTRACT
BACKGROUND:
As therapy for solid tumours, various tumour antigens have been selected as targets, but CAR-T cells targeting these antigens have shown limited efficacy, in contrast to the effectiveness of CAR-T cells targeting haematological malignancies. In a previous report, we identified a cancer-testis antigen, DNAJB8. DNAJB8 plays a major role in tumorigenicity in cancer stem-like cells/cancer-initiating cells (CSCs/CICs). Here, we report a DNAJB8-reactive CAR yielding anti-tumour effects against renal cell carcinoma (RCC) and osteosarcoma.METHODS:
We constructed a second-generation chimeric antigen receptor (CAR) against HLA-A*2402/DNAJB8-derived peptide (DNAJB_143) complex (B10 CAR). The reactivity of B10-CAR T cells against T2-A24 cells pulsed with the cognate peptide and an RCC and osteosarcoma cell lines were quantified. The effects of adoptive cell transfer (ACT) therapy were assessed using in vivo xenografted mice models.RESULTS:
B10 CAR-T cells recognised DNAJB8_143-pulsed T2-A24 cells and HLA-A*2402(+)/DNAJB8(+) renal cell carcinoma and osteosarcoma cell lines. Moreover, ACT using B10 CAR-T cells showed anti-tumour effects against RCC and osteosarcoma cells.CONCLUSION:
B10 CAR-T cells could show specific cytotoxicity against RCC and osteosarcoma cells in vitro and in vivo. B10 CAR-T cells targeting the CSC/CIC antigen DNAJB8 might be a candidate immunotherapy for carcinoma and sarcoma.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ósseas
/
Carcinoma de Células Renais
/
Osteossarcoma
/
Receptores de Antígenos Quiméricos
/
Neoplasias Renais
Limite:
Animals
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article